NRx Pharmaceuticals (NRXP) Scheduled to Post Earnings on Monday

NRx Pharmaceuticals (NASDAQ:NRXPGet Rating) will be posting its quarterly earnings results before the market opens on Monday, May 16th.

Shares of NRXP stock traded down $0.04 on Wednesday, reaching $1.27. 1,274 shares of the company were exchanged, compared to its average volume of 757,208. The company has a market cap of $84.63 million, a price-to-earnings ratio of -0.17 and a beta of 0.68. The company has a 50-day moving average of $2.37 and a 200-day moving average of $4.10. NRx Pharmaceuticals has a one year low of $1.28 and a one year high of $48.80.

A number of large investors have recently bought and sold shares of the business. JPMorgan Chase & Co. increased its stake in NRx Pharmaceuticals by 2,345.3% in the 4th quarter. JPMorgan Chase & Co. now owns 5,184 shares of the company’s stock valued at $25,000 after buying an additional 4,972 shares during the last quarter. Royal Bank of Canada purchased a new stake in NRx Pharmaceuticals in the 2nd quarter valued at about $93,000. State Street Corp purchased a new stake in NRx Pharmaceuticals in the 4th quarter valued at about $49,000. Geode Capital Management LLC grew its position in shares of NRx Pharmaceuticals by 32.8% during the 3rd quarter. Geode Capital Management LLC now owns 45,766 shares of the company’s stock valued at $424,000 after acquiring an additional 11,291 shares during the period. Finally, Cubist Systematic Strategies LLC bought a new position in shares of NRx Pharmaceuticals during the 4th quarter valued at approximately $56,000. Hedge funds and other institutional investors own 3.87% of the company’s stock.

NRx Pharmaceuticals Company Profile (Get Rating)

NRX Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders and life-threatening pulmonary diseases. Its products include ZYESAMI, an investigational drug that has completed a Phase IIb/III clinical study for COVID-19 related respiratory failure; and NRX-100 and NRX-101 oral therapeutics for the treatment of bipolar depression in patients with acute suicidal behavior/ideation and sub-acute suicidal ideation and behavior.

Recommended Stories

Receive News & Ratings for NRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.